Betta Short Long Term Debt vs Accounts Payable Analysis

300558 Stock   52.69  1.11  2.06%   
Betta Pharmaceuticals financial indicator trend analysis is way more than just evaluating Betta Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Betta Pharmaceuticals is a good investment. Please check the relationship between Betta Pharmaceuticals Short Long Term Debt and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Betta Pharmaceuticals Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Short Long Term Debt vs Accounts Payable

Short Long Term Debt vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Betta Pharmaceuticals Short Long Term Debt account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Betta Pharmaceuticals' Short Long Term Debt and Accounts Payable is 0.59. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Betta Pharmaceuticals Co, assuming nothing else is changed. The correlation between historical values of Betta Pharmaceuticals' Short Long Term Debt and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Betta Pharmaceuticals Co are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Short Long Term Debt i.e., Betta Pharmaceuticals' Short Long Term Debt and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.59
Relationship DirectionPositive 
Relationship StrengthWeak

Short Long Term Debt

The total of a company's short-term and long-term borrowings.

Accounts Payable

An accounting item on the balance sheet that represents Betta Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Betta Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Betta Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Betta Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Betta Pharmaceuticals Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
As of November 28, 2024, Selling General Administrative is expected to decline to about 632.6 M. The current year's Tax Provision is expected to grow to about (11 M)
 2021 2022 2023 2024 (projected)
Operating Income381.4M208.4M332.1M285.1M
Total Revenue2.2B2.4B2.5B1.4B

Betta Pharmaceuticals fundamental ratios Correlations

-0.260.940.980.940.930.710.910.910.89-0.140.980.940.960.990.660.970.880.860.920.96-0.750.810.780.830.93
-0.26-0.46-0.15-0.02-0.540.240.04-0.29-0.50.24-0.29-0.11-0.4-0.230.12-0.20.05-0.04-0.21-0.08-0.020.21-0.050.15-0.24
0.94-0.460.880.840.940.520.820.840.95-0.270.950.850.970.930.530.910.760.730.840.87-0.680.70.640.720.91
0.98-0.150.880.930.880.790.90.850.86-0.040.970.930.90.970.720.970.930.910.90.96-0.740.860.850.870.91
0.94-0.020.840.930.80.80.970.880.76-0.20.910.930.890.950.590.880.870.850.950.99-0.860.840.780.840.89
0.93-0.540.940.880.80.480.750.890.91-0.260.920.880.950.930.470.90.710.720.850.85-0.60.590.650.630.87
0.710.240.520.790.80.480.780.550.49-0.040.710.670.550.720.640.650.850.880.720.81-0.770.770.850.770.71
0.910.040.820.90.970.750.780.840.7-0.180.890.910.870.920.630.880.870.80.870.97-0.910.910.70.910.88
0.91-0.290.840.850.880.890.550.840.7-0.220.830.870.950.910.490.850.690.680.870.88-0.690.620.590.670.82
0.89-0.50.950.860.760.910.490.70.7-0.150.930.790.880.870.530.880.740.750.810.79-0.560.640.720.650.86
-0.140.24-0.27-0.04-0.2-0.26-0.04-0.18-0.22-0.15-0.16-0.19-0.27-0.240.35-0.070.040.05-0.14-0.220.210.110.170.09-0.26
0.98-0.290.950.970.910.920.710.890.830.93-0.160.930.930.980.640.960.890.870.910.95-0.760.810.810.820.94
0.94-0.110.850.930.930.880.670.910.870.79-0.190.930.890.960.610.950.860.80.890.95-0.770.80.70.820.89
0.96-0.40.970.90.890.950.550.870.950.88-0.270.930.890.960.530.920.750.730.880.91-0.710.690.630.730.91
0.99-0.230.930.970.950.930.720.920.910.87-0.240.980.960.960.60.960.870.850.930.98-0.780.790.770.810.94
0.660.120.530.720.590.470.640.630.490.530.350.640.610.530.60.720.790.660.490.61-0.510.750.570.770.62
0.97-0.20.910.970.880.90.650.880.850.88-0.070.960.950.920.960.720.90.820.840.92-0.690.840.730.860.91
0.880.050.760.930.870.710.850.870.690.740.040.890.860.750.870.790.90.940.790.9-0.790.920.840.950.9
0.86-0.040.730.910.850.720.880.80.680.750.050.870.80.730.850.660.820.940.850.87-0.760.820.950.850.88
0.92-0.210.840.90.950.850.720.870.870.81-0.140.910.890.880.930.490.840.790.850.93-0.790.70.830.720.86
0.96-0.080.870.960.990.850.810.970.880.79-0.220.950.950.910.980.610.920.90.870.93-0.850.850.80.860.92
-0.75-0.02-0.68-0.74-0.86-0.6-0.77-0.91-0.69-0.560.21-0.76-0.77-0.71-0.78-0.51-0.69-0.79-0.76-0.79-0.85-0.8-0.65-0.83-0.81
0.810.210.70.860.840.590.770.910.620.640.110.810.80.690.790.750.840.920.820.70.85-0.80.730.980.78
0.78-0.050.640.850.780.650.850.70.590.720.170.810.70.630.770.570.730.840.950.830.8-0.650.730.730.74
0.830.150.720.870.840.630.770.910.670.650.090.820.820.730.810.770.860.950.850.720.86-0.830.980.730.85
0.93-0.240.910.910.890.870.710.880.820.86-0.260.940.890.910.940.620.910.90.880.860.92-0.810.780.740.85
Click cells to compare fundamentals

Betta Pharmaceuticals Account Relationship Matchups

Betta Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets4.1B5.2B6.3B7.9B9.1B9.6B
Other Current Liab148.2M136.9M95.8M1.6M4.1M3.9M
Total Current Liabilities705.2M438.1M888.9M2.1B1.8B1.9B
Total Stockholder Equity2.5B4.1B4.6B4.8B5.3B5.5B
Other Liab227.3M678.9M644.6M690.4M794.0M833.7M
Accounts Payable29.2M113.6M431.2M591.0M800.1M840.1M
Cash521.3M1.3B792.0M731.3M752.0M466.3M
Other Assets1.1B1.5B1.3B1.3B1.5B1.6B
Net Receivables57.7M52.6M214.1M433.3M286.4M300.7M
Inventory134.6M188.6M293.3M372.2M327.5M343.9M
Other Current Assets78.7M63.9M153.5M93.8M140.4M147.4M
Total Liab1.7B1.1B1.6B3.0B3.8B4.0B
Intangible Assets1.4B1.8B2.4B2.7B3.2B3.3B
Property Plant Equipment815.1M789.9M775.7M1.3B1.5B1.6B
Retained Earnings1.4B1.9B2.1B2.0B2.3B1.2B
Net Tangible Assets1.3B1.5B3.1B3.0B3.4B2.0B
Other Stockholder Equity4.3M51.9M52.3M74.6M85.8M90.1M
Deferred Long Term Liab565.5M913.1M1.2B1.3B1.4B1.5B
Total Current Assets792.2M1.8B1.7B1.7B1.5B1.3B
Non Current Assets Total3.3B3.4B4.6B6.2B7.6B4.3B
Non Currrent Assets Other1.4M50.8M1.1M6.6M16.5M15.7M
Non Current Liabilities Total958.9M647.2M696.8M847.7M2.0B2.1B
Net Invested Capital3.1B4.1B4.6B5.9B7.4B4.8B
Net Working Capital87.0M1.4B765.1M(371.9M)(277.3M)(263.4M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Betta Stock

Balance Sheet is a snapshot of the financial position of Betta Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Betta Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Betta Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Betta currently owns. An asset can also be divided into two categories, current and non-current.